Related references
Note: Only part of the references are listed.Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Charles Butts et al.
LANCET ONCOLOGY (2014)
Antitumor Effects of Cisplatin Combined with Tecemotide Immunotherapy in a Human MUC1 Transgenic Lung Cancer Mouse Model
Chiao-Jung Kao et al.
CANCER IMMUNOLOGY RESEARCH (2014)
A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer
Michael A. Morse et al.
ANNALS OF SURGERY (2013)
TGF-β: Guardian of T Cell Function
Soyoung A. Oh et al.
JOURNAL OF IMMUNOLOGY (2013)
Antitumor effects of L-BLP25 Antigen-Specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model
Gregory T. Wurz et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Daniel P. Vang et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2013)
Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy
Chiao-Jung Kao et al.
ONCOIMMUNOLOGY (2013)
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases-a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial
Carl Christoph Schimanski et al.
BMC CANCER (2012)
MUC1 mucin is expressed on human T-regulatory cells: Function in both co-stimulation and co-inhibition
Jeffrey D. Konowalchuk et al.
CELLULAR IMMUNOLOGY (2012)
L-BLP25 Vaccine plus Letrozole Induces a TH1 Immune Response and Has Additive Antitumor Activity in MUC1-Expressing Mammary Tumors in Mice
Neelima R. Mehta et al.
CLINICAL CANCER RESEARCH (2012)
Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine
Vani Lakshminarayanan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
TG4010 A therapeutic vaccine against MUC1 expressing tumors
Jean-Marc Limacher et al.
ONCOIMMUNOLOGY (2012)
Synthetic Antitumor Vaccines Containing MUC1 Glycopeptides with Two Immunodominant Domains-Induction of a Strong Immune Response against Breast Tumor Tissues
Nikola Gaidzik et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2011)
INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
Yi-Long Wu et al.
BMC CANCER (2011)
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings
Stephane Oudard et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
Mahsa Mohebtash et al.
CLINICAL CANCER RESEARCH (2011)
Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas
Olivera J. Finn et al.
IMMUNOLOGIC RESEARCH (2011)
Safety of BLP25 Liposome Vaccine (L-BLP25) in Japanese Patients with Unresectable Stage III NSCLC after Primary Chemoradiotherapy: Preliminary Results from a Phase I/II Study
Fumiyoshi Ohyanagi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial
Charles Butts et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
Elisabeth Quoix et al.
LANCET ONCOLOGY (2011)
Antiestrogens Induce Transforming Growth Factor β-Mediated Immunosuppression in Breast Cancer
Christian M. Joffroy et al.
CANCER RESEARCH (2010)
Consecutive low doses of cyclophosphamide preferentially target T-regs and potentiate T cell responses induced by DNA PLG microparticle immunization
Christine M. Barbon et al.
CELLULAR IMMUNOLOGY (2010)
Tamoxifen counteracts the allergic immune response and improves allergen-induced dermatitis in mice
M. Babina et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2010)
A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
Charles Butts et al.
CLINICAL LUNG CANCER (2010)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2009)
The Effects of Tamoxifen on Immunity
S. Behjati et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Impact of glycans on T-cell tolerance to glycosylated self-antigens
Anthony W. Purcell et al.
IMMUNOLOGY AND CELL BIOLOGY (2008)
Challenges for cancer vaccine development
Z. Tabi et al.
ADVANCED DRUG DELIVERY REVIEWS (2006)
A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy
S. A. North et al.
JOURNAL OF UROLOGY (2006)
A randomized phase II study of docetaxel alone or in combination with PANVAC™-V (vaccinia) and PANVAC™-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229)
Philip M. Arlen et al.
CLINICAL BREAST CANCER (2006)
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer
C Butts et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Vaccination with BLP25 lipsome vaccine to treat non-small cell lung and prostate cancers
Scott North et al.
EXPERT REVIEW OF VACCINES (2005)
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
AM Ercolini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
MEC Lutsiak et al.
BLOOD (2005)
Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma
C Choi et al.
BLOOD (2005)
Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites
SK Lau et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2004)
O-linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells
FG Hanisch et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Cancer vaccines: Between the idea and the reality
OJ Finn
NATURE REVIEWS IMMUNOLOGY (2003)
MUC1 mucin in urological malignancy
DP Scholfield et al.
BJU INTERNATIONAL (2003)
Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer
P Mukherjee et al.
JOURNAL OF IMMUNOTHERAPY (2003)
Share Paper
